Komori
Sysmex (6869) · InitiativeFirst stated

Pre-Transplantation Immune Response Testing Method for RPE Cells Derived from Allogeneic iPS Cells

First written in FY2017. . Latest entry: FY2017.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Pre-Transplant Compatibility Testing Method for Allogeneic iPS Cell-Derived RPE CellsA theme 2 companies write about · 0 as a headwind · 2 as a tailwind

0 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2017First statedAnnual report

    「Our company, HEALIOS K.K. (hereinafter, “HEALIOS”) and Dainippon Sumitomo Pharma Co., Ltd. (hereinafter, “Dainippon Sumitomo Pharma”) have launched joint research and development to establish a method for testing immune responses before transplantation of allogeneic iPS cell-derived retinal pigment epithelial cells (RPE cells).」

    It began joint research and development among 3 companies, together with HEALIOS and Dainippon Sumitomo Pharma, on a pre-transplant immune-response testing method for allogeneic iPS cell-derived RPE cells.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Sysmex yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Pre-Transplantation Immune Response Testing Method for RPE Cells Derived from Allogeneic iPS Cells | SYSMEX CORPORATION (6869) | Komori